Embecta vs Organogenesis Holdings
Embecta is the larger business, with $1.08bn of revenue in fiscal 2025 against $564m for Organogenesis Holdings (1.9 times as much). Organogenesis Holdings grew faster (17.0% against -3.8%). Embecta kept more of each dollar of sales as profit: a net margin of 8.8% against 6.6%.
| Latest fiscal year | EmbectaEMBC, 2025 | Organogenesis HoldingsORGO, 2025 |
|---|---|---|
| Revenue | $1.08bn | $564m |
| Revenue growth | -3.8% | 17.0% |
| Net income | $95.4m | $37.0m |
| Operating margin | 22.4% | 7.9% |
| Net margin | 8.8% | 6.6% |
| Return on equity | — | 13.2% |
| Free cash flow | $182m | −$24.5m |
| Cash | $226m | $93.7m |
| Total debt | $1.42bn | $0 |
| Debt to equity | — | 0.0% |
| Dividend per share | $0.60 | — |
| Dividend yield | 7.8% | — |
| Share buybacks | — | — |
| Employees | 1,850 | 854 |
| Market value | $343m | $109m |
| Price vs our value range | — | — |
| Moat score | 70 (Moderate) | 56 (Moderate) |
| Insider trades, 12 months | 4 buys, 1 sales | 2 buys, 4 sales |